Table 4.
MRI brain volume characteristics of MS patients treated with teriflunomide or dimethyl fumarate over the follow-up.
| 0–12 Months | 12–24 Months | 0–24 Months | |||||||
|---|---|---|---|---|---|---|---|---|---|
| TFM (n = 60) | DMF (n = 57) | p-Value | TFM (n = 48) | DMF (n = 46) | p-Value | TFM (n = 48) | DMF (n = 46) | p-Value | |
| PBVC | −0.73 (1.4) | −0.92 (1.5) | 0.496 | −1.08 (1.2) | −1.4 (1.7) | 0.351 | −1.45 (1.5) | −2.07 (1.7) | 0.077 |
| PGMVC | −0.24 (3.9) | −1.71 (3) | 0.044 | −075 (5.1) | −1.33 (4.1) | 0.605 | −0.44 (5.2) | −3.12 (4.3) | 0.015 |
| PWMVC | −1.72 (4.7) | −1.19 (4.1) | 0.565 | −2.87 (5.1) | −2.24 (5.1) | 0.618 | −4.88 (4.8) | −4.17 (5.1) | 0.550 |
| PLVVC | 1.40 (5.2) | 3.56 (5.7) | 0.05 | 3.07 (7.5) | 2.25 (6.9) | 0.620 | 3.85 (10.2) | 6.26 (8.7) | 0.245 |
| PCVC | −0.29 (4) | −1.48 (3.2) | 0.115 | −0.79 (3.9) | −1.6 (3.3) | 0.358 | −0.20 (4.3) | −2.94 (3.9) | 0.004 |
| PTVC | −0.83 (4) | −1.20 (3.3) | 0.624 | −0.44 (5) | −1.1 (4.1) | 0.531 | −1.18 (5.5) | −1.87 (5) | 0.556 |
| PDGMVC | −0.5 (3.8) | −0.91 (3.2) | 0.557 | −0.34 (5.4) | −1.03 (4.4) | 0.538 | −1.0 (5.6) | −1.7 (4.2) | 0.515 |
Note: TFM-teriflunomide; DMF-dimethyl fumarate; PBVC-percentage brain volume change; PGMVC-percentage gray matter volume change; PWMVC-percentage white matter volume change; PLVVC-percentage lateral ventricle volume change; PCVC-percentage cortical volume change; PTVC-percentage thalamus volume change; PDGMVC-percentage deep GM volume change. p-values derived from ANCOVA, corrected for age and sex. p-values shown in bold and italics are ≤0.05 and ≤0.1, respectively.